Collegium Pharmaceutical, Inc. COLL
23.73 USD +0.05 (+0.21%)
At closeNov 3, 2026, 4:01 PM EST
23.73 0.00 0.00%
After hours · Nov 3, 4:01 PM ET
23.49 Day range 23.92
21.43 52-week range 50.79
- YTD
- -48.75%
- 1 year
- -34.27%
News
zacks.com Earnings Preview: Collegium Pharmaceutical (COLL) Q3 Earnings Expected to Decline Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
globenewswire.com Collegium Pharmaceutical and Boston Legacy FC Expand Their Partnership Beyond Matchday to Communities Across Massachusetts New multi-year partnership combines youth coach training, an annual Sports for All Summit, and sensory inclusion programs to support neurodivergent children and families New multi-year partnership…
globenewswire.com Collegium to Report Third Quarter 2026 Financial Results on November 5, 2026 STOUGHTON, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and…
globenewswire.com Collegium to Present Pediatric and Real-World Research Across ADHD Portfolio at AACAP and NEI Fall Congresses Seven presentations include pediatric Phase 4 studies of AZSTARYS® (Serdexmethylphenidate/dexmethylphenidate) CII and real-world research of JORNAY PM® (Delayed-Release/Extended-Release…
benzinga.com Collegium Pharmaceutical And Grünenthal Enter Settlement Agreement On Oct 15, 2026; Terminates Grünenthal License And Consent Agreement For Territory Effective Oct 15, 2026; Co. To Pay Grünenthal $17M In Settlement As previously disclosed, Collegium Pharmaceutical, Inc. (the "Company") is party to a License Agreement (U.S.), dated as of January 13, 2015, with Grünenthal GmbH ("Grünenthal") (as amended, the
zacks.com COLL vs. DSNKY: Which Stock Is the Better Value Option? Investors interested in Medical - Drugs stocks are likely familiar with Collegium Pharmaceutical (COLL) and Daiichi Sankyo Co., Ltd. - Sponsored ADR (DSNKY).
seekingalpha.com Collegium Pharmaceutical: Under 3x Cash Earnings After A Narrow Guidance Cut Collegium Pharmaceutical is rated a high-risk Buy after a sharp guidance cut and stock drop, with the market pricing in an overly pessimistic scenario. ADHD drugs Jornay PM and AZSTARYS now account…
zacks.com Does Collegium Pharmaceutical (COLL) Have the Potential to Rally 111.39% as Wall Street Analysts Expect? The consensus price target hints at an 111.4% upside potential for Collegium Pharmaceutical (COLL). While empirical research shows that this sought-after metric is hardly effective, an upward trend…
zacks.com New Strong Sell Stocks for October 7th ARDX, LUV and COLL have been added to the Zacks Rank #5 (Strong Sell) List on October 7th, 2026.
globenewswire.com Collegium Launches "Start Talking ADHD" with Practical Support to Help Families Navigate Care, School and Everyday Life STOUGHTON, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and…
benzinga.com Collegium Pharmaceutical Reports Q2 2026 Results: Full Earnings Call Transcript Collegium Pharmaceutical (NASDAQ:COLL) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This content is powered by Benzinga APIs.…
benzinga.com Oppenheimer Initiates Coverage On Collegium Pharmaceutical with Outperform Rating, Announces Price Target of $50 Oppenheimer analyst Les Sulewski initiates coverage on Collegium Pharmaceutical (NASDAQ:COLL) with a Outperform rating and announces Price Target of $50.
seekingalpha.com Collegium Pharmaceutical, Inc. (COLL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Collegium Pharmaceutical, Inc. (COLL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
benzinga.com Truist Securities Maintains Buy on Collegium Pharmaceutical, Lowers Price Target to $49 Truist Securities analyst Alexander Xenakis maintains Collegium Pharmaceutical (NASDAQ:COLL) with a Buy and lowers the price target from $58 to $49.
benzinga.com Leerink Partners Initiates Coverage On Collegium Pharmaceutical with Outperform Rating, Announces Price Target of $45 Leerink Partners analyst Daniel Clark initiates coverage on Collegium Pharmaceutical (NASDAQ:COLL) with a Outperform rating and announces Price Target of $45.
globenewswire.com Collegium to Participate in Upcoming Investor Conferences STOUGHTON, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious…
benzinga.com Top 3 Health Care Stocks Which Could Rescue Your Portfolio In Q3 Healthcare stocks UTHR, COLL and AHG show oversold RSI levels near or below 30, potentially offering undervalued buying opportunities.
defenseworld.net 44,493 Shares in Collegium Pharmaceutical, Inc. $COLL Purchased by Freestone Grove Partners LP Freestone Grove Partners LP bought a new stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ: COLL) in the second quarter, according to its most recent 13F filing with the Securities and…
defenseworld.net BlackRock Inc. Takes $196.97 Million Position in Collegium Pharmaceutical, Inc. $COLL BlackRock Inc. bought a new position in Collegium Pharmaceutical, Inc. (NASDAQ: COLL) during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange…
gurufocus.com A Look at Collegium Pharmaceutical Inc (COLL) After 3.9% Decline -- GF Value $47.17 vs Price $26.39 On August 27, 2026, Collegium Pharmaceutical Inc (COLL) shares fell 3.9% to a current price of $26.39. Over the past year, the stock has seen significant volati
benzinga.com Barclays Maintains Overweight on Collegium Pharmaceutical, Lowers Price Target to $48 Barclays analyst Glen Santangelo maintains Collegium Pharmaceutical (NASDAQ:COLL) with a Overweight and lowers the price target from $56 to $48.
globenewswire.com Collegium Announces $50 Million Accelerated Share Repurchase Program STOUGHTON, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and…
defenseworld.net Avenue Therapeutics (NASDAQ:ATXI) and Collegium Pharmaceutical (NASDAQ:COLL) Head-To-Head Survey Collegium Pharmaceutical (NASDAQ: COLL - Get Free Report) and Avenue Therapeutics (NASDAQ: ATXI - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will…
benzinga.com Piper Sandler Reiterates Neutral on Collegium Pharmaceutical, Lowers Price Target to $43 Piper Sandler analyst David Amsellem reiterates Collegium Pharmaceutical (NASDAQ:COLL) with a Neutral and lowers the price target from $45 to $43.
seekingalpha.com Collegium Pharmaceutical, Inc. (COLL) Q2 2026 Earnings Call Transcript Collegium Pharmaceutical, Inc. (COLL) Q2 2026 Earnings Call Transcript- benzinga.com Needham Maintains Buy on Collegium Pharmaceutical, Lowers Price Target to $46 Needham analyst Serge Belanger maintains Collegium Pharmaceutical (NASDAQ:COLL) with a Buy and lowers the price target from $56 to $46.
zacks.com Collegium Pharmaceutical (COLL) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates Although the revenue and EPS for Collegium Pharmaceutical (COLL) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare…
zacks.com Collegium Pharmaceutical (COLL) Beats Q2 Earnings and Revenue Estimates Collegium Pharmaceutical (COLL) came out with quarterly earnings of $1.92 per share, beating the Zacks Consensus Estimate of $1.68 per share. This compares to earnings of $1.68 per share a year ago.
marketbeat.com Collegium Pharmaceutical Q2 Earnings Call Highlights Collegium Pharmaceutical NASDAQ: COLL reported second-quarter 2026 net product revenue of $199.9 million, up 6% from a year earlier, as growth in its ADHD franchise and BELBUCA helped offset lower…- benzinga.com Collegium Pharmaceutical Lowers FY2026 Sales Guidance from $865.000M-$895.000M to $825.000M-$855.000M vs $872.278M Est Collegium Pharmaceutical (NASDAQ:COLL) lowers FY2026 sales outlook from $865.000 million-$895.000 million to $825.000 million-$855.000 million vs $872.278 million estimate.
benzinga.com Collegium Pharmaceutical Affirms FY2026 Sales Guidance of $805.000M-$825.000M vs $825.757M Est Collegium Pharmaceutical (NASDAQ:COLL) affirms FY2026 sales outlook from $805.000 million-$825.000 million to $805.000 million-$825.000 million vs $825.757 million estimate.- benzinga.com Collegium Pharmaceutical Q1 Adj. EPS $1.76 Beats $1.59 Estimate, Sales $193.520M Beat $185.984M Estimate Collegium Pharmaceutical (NASDAQ:COLL) reported quarterly earnings of $1.76 per share which beat the analyst consensus estimate of $1.59 by 10.69 percent. This is a 18.12 percent increase over…
benzinga.com HC Wainwright & Co. Reiterates Buy on Collegium Pharmaceutical, Maintains $60 Price Target HC Wainwright & Co. analyst Brandon Folkes reiterates Collegium Pharmaceutical (NASDAQ:COLL) with a Buy and maintains $60 price target.
benzinga.com Collegium To Acquire AZSTARYS For $650M In Cash With Potential For Additional Milestone Payments Up To $135M Depending On Future Commercial And Regulatory Milestones – Adds Highly Complementary and Differentiated Medicine with Significant Growth Potential to Collegium's Existing ADHD Portfolio –– Enables Greater Impact Across ADHD Patient Communities –– AZSTARYS…
benzinga.com Deep Dive Into Collegium Pharmaceutical Stock: Analyst Perspectives (5 Ratings) 
benzinga.com Needham Maintains Buy on Collegium Pharmaceutical, Lowers Price Target to $54 Needham analyst Serge Belanger maintains Collegium Pharmaceutical (NASDAQ:COLL) with a Buy and lowers the price target from $56 to $54.- benzinga.com Collegium Pharmaceutical Sees FY2026 Sales $805.000M-$825.000M vs $808.877M Est Collegium Pharmaceutical (NASDAQ:COLL) sees FY2026 sales of $805.000 million-$825.000 million vs $808.877 million analyst estimate.
benzinga.com Insights into Collegium Pharmaceutical Q4 Earnings - benzinga.com Collegium Pharmaceutical Q4 Adj. EPS $2.04 Misses $2.33 Estimate, Sales $205.449M Miss $206.362M Estimate Collegium Pharmaceutical (NASDAQ:COLL) reported quarterly earnings of $2.04 per share which missed the analyst consensus estimate of $2.33 by 12.37 percent. This is a 15.25 percent increase over…
benzinga.com Earnings Scheduled For February 26, 2026 
benzinga.com Earnings Scheduled For November 6, 2025 - benzinga.com Earnings Scheduled For August 7, 2025
- benzinga.com Earnings Scheduled For May 8, 2025
- benzinga.com Earnings Scheduled For February 27, 2025
- benzinga.com Earnings Scheduled For February 22, 2024 Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is likely to report quarterly earnings at $0.28 per share on revenue of $260.00 million.
- benzinga.com Earnings Scheduled For November 7, 2023 Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings for its third quarter.
- benzinga.com Atlassian, Universal Display, Booking, Dropbox And Other Big Stocks Moving Higher On Friday U.S. stocks traded higher, with the Dow Jones gaining around 150 points on Friday. Here are some big stocks recording gains in today’s session.
- benzinga.com Earnings Scheduled For August 3, 2023 Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings at $1.10 per share on revenue of $512.74 million.
- benzinga.com Earnings Scheduled For May 4, 2023 Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is estimated to report quarterly loss at $1.83 per share on revenue of $104.21 million.
- benzinga.com Earnings Scheduled For February 23, 2023 Companies Reporting Before The Bell • ChipMOS TECHNOLOGIES (NASDAQ:IMOS) is likely to report earnings for its fourth quarter.